Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Dormant

Current status date:

2023-12-03

Original market date: See footnote 1

2021-04-21

Product name:

RIABNI

Description:

SINGLE-USE VIAL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02513447

Product Monograph/Veterinary Labelling:

Date: 2021-03-11 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

AMGEN CANADA INC
300 6775 Financial Drive
Mississauga
Ontario
Canada L5N 0A4

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

1

Schedule(s):

Schedule D ,  Prescription

Biosimilar Biologic Drug:

Yes

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01FA01 RITUXIMAB

Active ingredient group (AIG) number:See footnote5

0140241001

List of active ingredient(s)
Active ingredient(s) Strength
RITUXIMAB 10 MG / ML

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Version 4.0.2
Date modified: